Orally Administered DNA Vaccine Delivery by Attenuated Salmonella typhimurium Targeting Fetal Liver Kinase 1 Inhibits Murine Lewis Lung Carcinoma Growth and Metastasis
スポンサーリンク
概要
- 論文の詳細を見る
The vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2), also called fetal liver kinase 1 (FLK1) in mice and kinase insert domain receptor (KDR) in humans, is an endothelial cell specific receptor tyrosine kinase that mediates lung cancer angiogenesis. We hypothesized that an active immunotherapy approach targeting FLK1 may inhibit lung cancer growth and metastasis. To test this hypothesis, we evaluated whether immune responses to FLK1 could be elicited in mice by immunization with an orally administered DNA vaccine encoding the extracellular domain (ECD) of FLK1 (pcDNA3.1-FLK1ECD) carried by attenuated Salmonella typhimurium. We found that the vaccine was effective at protective antitumor immunity in Lewis lung carcinoma models in mice by breaking immune tolerance to FLK1 self-antigen. Both FLK1-specific humoral and cellular immune responses against endothelial cells can be induced in mice by immunization with pcDNA3.1-FLK1ECD. Immunization with pcDNA3.1-FLK1ECD resulted in tumor suppression and prolonged survival in mice challenged with Lewis lung carcinomas cells. Experimental pulmonary metastases were strongly inhibited in pcDNA3.1-FLK1ECD immunized mice challenged with Lewis lung carcinoma cells. Thus, we conclude that the plasmid DNA vaccine encoding the extracellular domain of FLK1 could be an important component of FLK1 DNA vaccine to prevent lung carcinoma recurrence and metastasis after surgery.
著者
-
Zuo Shu
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Chen Yan
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Wu Zhi
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Liu Xin
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Liu Chun
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Zhou Yong
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Wu Cui
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Jin Cong
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Gu Yu
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Li Jia
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Chen Xiao
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Li Yong
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Wei Hui
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Li Li
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Wang Xi
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tum
-
Zhou Yong
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Li Jia
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Liu Xin
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Jin Cong
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Wu Zhi
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Wang Xi
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Wei Hui
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Liu Chun
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)
-
Chen Xiao
Tumor Institute of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province)